Definium Therapeutics (DFTX) Net Cash Flow (2021 - 2026)

Definium Therapeutics (DFTX) has 6 years of Net Cash Flow data on file, last reported at $4.7 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 102.45% year-over-year to $4.7 million in Q1 2026; TTM through Mar 2026 was $179.7 million, a 206.02% increase from a year earlier, with the FY2025 full-year figure at -$15.9 million, down 109.13% from the prior year.
• Net Cash Flow for Q1 2026 stood at $4.7 million, down from $237.9 million in the prior quarter.
• Over the last five years, Net Cash Flow for DFTX reached as high as $237.9 million in Q4 2025 and fell as low as -$190.9 million in Q1 2025.
• Historically, Net Cash Flow has averaged $7.6 million across 5 years, with a median of -$12.6 million in 2023.
• Across the five-year window, Net Cash Flow jumped 6656.87% in 2024 and tumbled 437.84% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$12.4 million in 2022, then tumbled by 44.53% to -$18.0 million in 2023, then fell by 19.89% to -$21.5 million in 2024, then jumped by 1204.15% to $237.9 million in 2025, then plunged by 98.03% to $4.7 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $4.7 million in Q1 2026, $237.9 million in Q4 2025, and -$13.4 million in Q3 2025.